Clinical Trials on Hepatitis B in New Zealand

Total 1697 results

Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
Assembly Biosciences

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

Chronic Hepatitis B

New Zealand
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Assembly Biosciences

Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand
Arrowhead Pharmaceuticals

Terminated

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Hepatitis B

New Zealand
Assembly Biosciences

Completed

A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects

Chronic Hepatitis B

New Zealand
Novira Therapeutics, Inc.

Completed

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Chronic Hepatitis B

New Zealand
Virion Therapeutics

Recruiting

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Chronic Hepatitis B

Hong Kong, New Zealand
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Chronic Hepatitis B

New Zealand
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Novartis
Novartis Pharmaceuticals

Completed

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Hepatitis B

Hong Kong, Singapore, New Zealand
Gilead Sciences

Completed

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Chronic Hepatitis B

United States, New Zealand
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hepatitis B, Chronic

New Zealand
Hoffmann-La Roche

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

Hong Kong, Taiwan, New Zealand
Aligos Therapeutics

Terminated

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Chronic Hepatitis B

New Zealand, Bulgaria, Moldova, Republic of, Romania
Arbutus Biopharma Corporation

Completed

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Hepatitis B, Chronic

Australia, New Zealand
Abivax S.A.

Completed

Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand, Australia
Alios Biopharma Inc.

Completed

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Moldova, Republic of, New Zealand, Thailand, Ukraine
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand
Alnylam Pharmaceuticals

Terminated

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B | Chronic Hepatitis B | Hepatitis B, Chronic | HBV | Hepatitis B Infection

United Kingdom, New Zealand, Singapore, Korea, Republic of, Australia, Hong Kong
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Hepatitis B Virus

United States, Germany, New Zealand
Assembly Biosciences

Completed

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Singapore, Hong Kong, Bulgaria, Moldova, Republic of, New Zealand, Romania
AusperBio Therapeutics Inc.

Active, not recruiting

A Study Evaluating AHB-137 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

United States, Hong Kong, Taiwan, New Zealand
Assembly Biosciences

Terminated

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Chronic Hepatitis B

Hong Kong, United States, New Zealand
Hoffmann-La Roche

Terminated

A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Hepatitis B Virus Infection

United Kingdom, Hong Kong, Korea, Republic of, Taiwan, Poland, Bulgaria, New Zealand
Aligos Therapeutics

Terminated

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Korea, Republic of, China, Hong Kong, United Kingdom, New Zealand, Moldova, Republic of
Hoffmann-La Roche

Completed

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

Hepatitis B, Chronic

Taiwan, United States, New Zealand, Singapore
Hoffmann-La Roche

Completed

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Hepatitis B, Chronic

Taiwan, United States, New Zealand, Singapore
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Completed

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, New Zealand, Thailand
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)

Hepatitis B, Chronic

Taiwan, Poland, Japan, New Zealand
Assembly Biosciences

Completed

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

Chronic Hepatitis B

New Zealand, United States, Canada
Gilead Sciences

Completed

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

Chronic HBV Infection

United States, New Zealand
Aligos Therapeutics

Recruiting

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Hong Kong, China, United Kingdom, Moldova, Republic of, New Zealand, Australia, Mauritius
Assembly Biosciences

Completed

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Chronic Hepatitis B

United States, Canada, Hong Kong, New Zealand, United Kingdom
Assembly Biosciences

Completed

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Australia, United States, Hong Kong, United Kingdom, China, New Zealand
Janssen Research & Development, LLC

Completed

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (INSIGHT)

Hepatitis B

France, United States, Belgium, United Kingdom, Poland, New Zealand, Germany, Italy, Canada
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Taiwan, Thailand, New Zealand, Singapore
Novartis
Novartis Pharmaceuticals

Completed

Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B

Chronic Hepatitis B

United States, United Kingdom, China, Taiwan, Canada, Singapore, New Zealand, Australia, France, Israel, Thailand
Dicerna Pharmaceuticals, Inc.

Completed

Study of Safety and Tolerability of DCR HBVS

Hepatitis B, Chronic

Korea, Republic of, New Zealand, Australia, Thailand, Hong Kong
Assembly Biosciences

Terminated

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Chronic Hepatitis B

United States, Canada, Hong Kong, New Zealand, United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Korea, Republic of, United States, Thailand, Hong Kong, Spain, New Zealand, Bulgaria, Taiwan, France
Gilead Sciences
Vir Biotechnology, Inc.

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Chronic Hepatitis B

Hong Kong, Korea, Republic of, Denmark, Australia, Thailand, Singapore, United Kingdom, New Zealand
Vir Biotechnology, Inc.

Completed

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Germany, Hong Kong, Korea, Republic of, New Zealand, Romania, Singapore, United Kingdom
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Hepatitis B

Korea, Republic of, United States, Canada, Australia, New Zealand
Assembly Biosciences
Arbutus Biopharma Corporation

Terminated

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Chronic Hepatitis B

Australia, Canada, Bulgaria, New Zealand
Hoffmann-La Roche

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic, Healthy Volunteer

New Zealand

3

Subscribe